A Markov mixed effect regression model for drug compliance.
about
Pharmacodynamic models for discrete data.Analysis of population pharmacokinetic data using NONMEM and WinBUGS.Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models.The back-step method--method for obtaining unbiased population parameter estimates for ordered categorical dataClustering based on adherence data.Modeling sleep data for a new drug in development using markov mixed-effects models.Screening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: utility of population analysis.A hybrid Markov chain-von Mises density model for the drug-dosing interval and drug holiday distributions.Clinical trial simulation: a tool for understanding study failures and preventing them.Modeling and simulation of adherence: approaches and applications in therapeutics.Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies.Triptan persistency among newly initiated users in a pharmacy claims database.Impact of disease, drug and patient adherence on the effectiveness of antiviral therapy in pediatric HIV.Markov Mixed Effects Modeling Using Electronic Adherence Monitoring Records Identifies Influential Covariates to HIV Preexposure Prophylaxis.Quantification of the Forgiveness of Drugs to Imperfect Adherence.A Mathematical Model to Predict HIV Virological Failure and Elucidate the Role of Lymph Node Drug Penetration.Bayesian population modeling of drug dosing adherence.Estimation of the impact of noncompliance on pharmacokinetics: an analysis of the influence of dosing regimens.Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide.Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients.Compliance spectrum as a drug fingerprint of drug intake and drug disposition.
P2860
Q30578472-F8A36D5D-DE2A-4B14-97AE-BCCACFC13D31Q30982415-1A0AA530-1B08-484E-9F56-850B95B2C2FCQ30985350-A5D95B58-1B36-4CCA-82D1-B1725EEE9D1AQ33212737-E6491C5F-9DBA-4DDA-8F82-FBE5BBDCC7F7Q33840321-0D5534B3-68EC-4305-806F-2AC86F73990CQ33935102-DF0EE80F-F8FC-4EE1-964E-E7FA4B4309C6Q34211026-3AE8411B-1176-45BA-9EEB-9F16ED758C6BQ35192888-FA7A51D5-9A95-404A-8C7B-214EE6BD7A8DQ36055589-C7ECC994-A25C-46C7-ACBB-D9B0066FEEE3Q36341606-E4FFA01C-333F-46C4-A404-DF3C689C6401Q36747438-C16BE023-18DA-4B1C-A484-552956AE13C7Q37210864-4418DCD6-605B-4B00-9B11-92FDB9AA3E40Q37799448-4013F77D-D047-4AA2-ADA7-2628AE981755Q39064765-E9CD5E8B-58B6-4A58-92FB-506D1BD718B2Q39127005-0452FE25-C44E-48BE-BAF7-A871BA51A3D5Q39559341-76C8E6A7-E175-4392-B64E-5BCA8AD717A6Q40181126-0B456AB6-26FE-4031-A501-34B910BA5F77Q40594262-5A4111BD-118C-49F1-BF66-1BFE83CF2B7CQ40943722-8A4D6A59-B0E3-4BDC-A3EF-9303C80DA9ECQ42117272-30A4BA06-93C8-43EB-A493-4719A4499932Q43260037-201BC720-0835-4758-B0B8-355BEF79CDCBQ51286554-4BDE7DE8-A64C-4561-8657-5A62C5C0AD03
P2860
A Markov mixed effect regression model for drug compliance.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
A Markov mixed effect regression model for drug compliance.
@en
type
label
A Markov mixed effect regression model for drug compliance.
@en
prefLabel
A Markov mixed effect regression model for drug compliance.
@en
P2093
P1476
A Markov mixed effect regression model for drug compliance.
@en
P2093
Blaschke TF
Kastrissios H
Sheiner LB
P304
P356
10.1002/(SICI)1097-0258(19981030)17:20<2313::AID-SIM935>3.0.CO;2-V
P407
P577
1998-10-01T00:00:00Z